Application of in silico approaches to predicting drug-drug interactions

Journal of Pharmacological and Toxicological Methods

Volumn 45, Issue 1, 2001, Pages 65-69

  Ekins, Sean ^a   Wrighton, Steven A ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

ADME; CYP1; Drug drug interactions; In silico

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2D6; HYPERFORIN; HYPERICIN;

ANALYTIC METHOD; CALCULATION; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG RESEARCH; ENZYME SUBSTRATE COMPLEX; HUMAN; NONHUMAN; PHARMACOPHORE; PREDICTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0034902212     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1056-8719(01)00119-8     Document Type: Article

References (45)

1. Molecular modeling of mammalian cytochrome P450s
2. A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6
3. Novel approach to predicting P450-mediated drug metabolism: Development of a combined protein and pharmacophore model for CYP2D6
4. Theoretical investigation of substrate specificity for cytochromes P450 1A2, P450 IID6 and P450 IIIA4
5. Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors
6. Three dimensional-quantitative structure activity relationship (3D-QSAR) analyses of inhibitors for CYP3A4
7. Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors
8. Three dimensional-quantitative structure activity relationship (3D-QSAR) analyses of substrates for CYP2B6
9. Three dimensional quantitative structure activity relationship (3D-QSAR) analysis of CYP3A4 substrates
10. Three dimensional-quantitative structure activity relationship computational approaches for prediction of human in vitro intrinsic clearance
11. Predicting drug-drug interactions in silico using pharmacophores: A paradigm for the next millenium
12. Present and future in vitro approaches for drug metabolism
13. Progress in predicting human ADME parameters in silico
14. Quinolone antibacterial agents: Relationship between structure and in vitro inhibition of human cytochrome P450 isoform CYP1A2
15. Systematic screening for pharmacokinetic interactions during drug development
16. m
17. Quantitative relationships between lipophilic character and drug metabolism
18. Structure-activity correlations in the metabolism of drugs
19. Quantitative structure-activity relationships of cytochrome P-450
20. Putative active site template model for cytochrome P4502C9 (tolbutamide hydroxylase)
21. Three-dimensional quantitative structure-activity relationship for inhibitors of cytochrome P4502C9
22. Predicting the cytochrome P450 mediated metabolism of xenobiotics
23. Quantitative structure activity relationships in substrates, inducers, and inhibitors of cytochrome P4501 (CYP1)
24. On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics
25. Structural characteristics of human P450s involved in drug metabolism: QSARs and lipophilicity profiles
26. Structural determinants of cytochrome P450 substrate specificity, binding affinity and catalytic rate
27. Erratum to structural determinants of cytochrome P450 substrate specificity, binding affinity and catalytic rate
28. Molecular modelling and quantitative structure-activity relationship studies on the interaction of omeprazole with cytochrome P450 isozymes
29. The substrate binding site of human liver cytochrome P4502C9: An approach using designed tienilic acid derivatives and molecular modeling
30. Inhibition of human cytochrome P450 enzymes by constituents of St. John's wort, an herbal preparation used in the treatment of depression
31. Comparative molecular field analysis of compounds with CYP2A5 binding affinity
32. A refined 3-dimensional QSAR of P4502C9
33. Properties of cytochrome P450 isoenzymes and their substrates: Part 1. Active site characteristics
34. Properties of cytochrome P450 isoenzymes and their substrates: Part 2. Properties of cytochrome P450 substrates
35. Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes
36. Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: Molecular modeling and inhibition studies
37. Molecular modeling of mammalian cytochromes P450: Application to study enzyme function
38. Use of homology modeling in conjunction with site-directed mutagenesis for analysis of structure-function relationships of mammalian cytochromes P450
39. Molecular basis of P450 inhibition and activation implications for drug development and drug therapy
40. Modeling the cytochrome P450-mediated metabolism of chlorinated volatile organic compounds
41. Screening studies for metabolism and toxicology
42. The human hepatic cytochromes P450 involved in drug metabolism